A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanistic studies and limited clinical data without systematic methodology.
PubMed 34542202 · doi:10.1002/ptr.7290
What was done
The authors conducted a narrative review summarizing the pharmacokinetics, biological activities, and molecular mechanisms of urolithins (gut microbial metabolites of dietary ellagitannins from foods such as pomegranates, walnuts, and berries) across in vitro, in vivo, and preliminary clinical studies.
What was found
The abstract reports no pooled quantitative outcome data. It notes that urolithins modulate molecular pathways by inhibiting MDM2-p53 interaction, modulating MAPK signaling, and suppressing NF-κB activity. Urolithin A activates mitophagy and mitochondrial biogenesis, and one cited clinical trial reported safety up to 2,500 mg/day alongside improvements in mitochondrial biomarkers in elderly patients.
Why it matters
It consolidates mechanistic pathways linking gut microbial metabolites of ellagitannins to anti-aging, metabolic, and anti-inflammatory effects, supporting further clinical testing of urolithin A for mitochondrial health.
Limits
This is a narrative review without systematic search or meta-analytic pooling. Most underlying evidence derives from cell culture and animal models, which may not translate to clinical outcomes. Specific patient numbers and effect sizes are not reported in the abstract.
Cited by
- supports Urolithin A is a metabolite produced by the gut microbiome from ellagitannin polyphenols found in foods like pomegranates, raspberries, and walnuts.